Ratos subsidiary Biolin Scientific Holding AB has divested Analytical Instruments (Biolin Scientific AB), a subsidiary in the Biolin Group, to the listed company AddLife. The sale is not expected to generate a significant exit gain for Ratos.
Ratos acquired Biolin Scientific in 2010, and the company currently offers advanced analysis instruments that help scientists and enterprises to scientifically analyse materials, nanotechnologies and pharmaceuticals faster and better. Biolin Scientific's operations are conducted in two independent subsidiaries today called Analytical Instruments and Drug Discovery. In conjunction with the divestment of Analytical Instruments, Drug Discovery will be run as an independent company in Ratos under the name Sophion, and shared Group-wide resources will be discontinued. Analytical Instruments has about 60 employees, with annual sales of approximately SEK 100m and operating EBITA of approximately SEK 6m based on the most recent 12 months as per September 2016.
"We have chosen to divest Analytical Instruments to AddLife, which will become a new, long-term owner with similar operations in Life Science. At the same time, this will enable increased focus on Sophion's core operations as an independent company," says Christina Rubenhag, CEO of Biolin Scientific Holding.
The divestment is not expected to generate a significant exit gain for Ratos. Sophion will be recognised as other net assets in Ratos's accounts for the full year 2016.
For further information, please contact:
Magnus Agervald, CEO Ratos, +46 8 700 17 00
Elin Ljung, Head of Corporate Communications Ratos, +46 8 700 17 20